RAD17 and gastric adenocarcinoma: RAD17 is frequently deleted in adenoid cystic carcinoma (13.3%) and prostate adenocarcinoma (13.1%, 5.9%) and frequently mutated in pancreatic adenocarcinoma (7.0%) and stomach adenocarcinoma (4.5%) (Figure 1B and 1C).